AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2961356
Drug: Intravenous Cl2MDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Cl2MDP (2.5 mg/kg on the first day and 5 mg/kg daily for up to 6 days)
Trial: 29053231
Drug: Nasal glucagon
RxNorm normalized name: glucagon Nasal Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal glucagon (NG) administered while experiencing nasal congestion (Cohort 1)
Trial: 29053231
Drug: Nasal glucagon
RxNorm normalized name: glucagon Nasal Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal glucagon (NG) administered after treatment with oxymetazoline (Cohort 2)
Trial: 29053231
Drug: Nasal glucagon
RxNorm normalized name: glucagon Nasal Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal glucagon (NG) administered with nasal congestion (Cohort 1)
Trial: 29053231
Drug: Nasal glucagon
RxNorm normalized name: glucagon Nasal Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal glucagon (NG) administered after recovery from cold symptoms (Cohort 1)
Trial: 29053231
Drug: Nasal glucagon
RxNorm normalized name: glucagon Nasal Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal glucagon (NG) administered with concomitant nasal decongestant (Cohort 2)
Trial: 24942096
Drug: Buccal sulcus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal sulcus approach
Trial: 24942096
Drug: Intranasal approach
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal approach
Trial: 18524691
Drug: 10-session, therapist-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-session, therapist-administered CBT
Trial: 18524691
Drug: 4-session, patient-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-session, patient-administered CBT
Trial: 9851273
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 15 mg weekly i.m. injections for 12 months
Trial: 9851273
Drug: Gold sodium
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold sodium thiomalate (GSTM) 50 mg weekly i.m. injections for 12 months
Trial: 2643296
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2 by 48‐h continuous i.v. infusion every 3 weeks)
Trial: 2643296
Drug: Epirubicin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (90 mg/m2 by 48‐h continuous i.v. infusion every 3 weeks)
Trial: 2643296
Drug: Epirubicin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (90 mg/m2 by bolus every 3 weeks)
Trial: 766791
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine with adrenaline 5 mug/ml
Trial: 766791
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine with adrenaline 5 mug/ml
Trial: 6105336
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg PolyA.PolyU intravenously per week for 6 weeks
Trial: 30712716
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (4 capsules of 500 mg daily for 3 days)
Trial: 30712716
Drug: Trimethoprim-sulfamethoxazole (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (standard antimicrobial treatment)
Trial: 30712716
Drug: Starch (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch (placebo, 4 capsules daily for 3 days)
Trial: 29093283
Drug: S‐NAC (surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐NAC (surgery with N-acetylcysteine 600 mg)
Trial: 23406981
Drug: Citicoline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (1 g/day) for 12 months
Trial: 18427456
Drug: Galantamine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (maximum dose 16 mg/day)
Trial: 15701301
Drug: Complementary and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary and alternative medicines (CAM)
Trial: 11969062
Drug: Alternative medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternative medicines with inhibitory effects on the coagulation cascade
Trial: 11969062
Drug: Alternative medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternative medicines affecting blood pressure
Trial: 11969062
Drug: Alternative medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternative medicines affecting cardiac function
Trial: 11969062
Drug: Alternative medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternative medicines causing sedation
Trial: 11969062
Drug: Alternative medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alternative medicines with potential to alter electrolyte levels
Trial: 11969062
Drug: Herbs recognized
RxNorm normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbs recognized to interact with pharmaceuticals
Trial: 9831574
Drug: Milk plus
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk plus one designated food daily
Trial: 2680178
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate cream twice daily
Trial: 2680178
Drug: Betamethasone dipropionate
RxNorm normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone dipropionate cream once daily with base cream in the evening
Trial: 765293
Drug: Cyclazocine, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclazocine, 4 mg administered daily
Trial: 765293
Drug: Naloxone, 500-2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone, 500-2,000 mg administered on a contingent basis
Trial: 21303569
Drug: Fe-fortified fruit
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fe-fortified fruit juice (500 ml/d providing 18 mg Fe/d)
Trial: 21303569
Drug: Placebo fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo fruit juice (500 ml/d)
Trial: 19494532
Drug: Metformin (1,700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,700 mg/day) for 12 weeks
Trial: 19494532
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg/day) for 12 weeks
Trial: 19494532
Drug: Simvastatin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (maximum dose 20 mg/day) in a subset of patients (n = 9)
Trial: 17719288
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (including ramipril)
Trial: 12508627
Drug: Directly Observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Observed Therapy Short Course (DOTS)
Trial: 12508627
Drug: Self Administered
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self Administered Therapy (SAT)
Trial: 9660578
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg three times daily
Trial: 17950105
Drug: Atorvastatin (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (average dosage, 20.8 mg/d)
Trial: 18566295
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and Fenofibrate
Trial: 9205766
Drug: Ebrotidine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine 800 mg/d p.o. (Group A)
Trial: 9205766
Drug: Indometacin 4
RxNorm normalized name: Indometacine
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indometacin 4 mg/kg/d p.o. in 3 divided doses (Group B)
Trial: 9205766
Drug: Ebrotidine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebrotidine 800 mg/d p.o. plus Indometacin 4 mg/kg/d p.o. (Group C)
Trial: 8280546
Drug: Background infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background infusion 10 micrograms kg-1 h-1 (B10)
Trial: 8280546
Drug: Background infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background infusion 4 micrograms kg-1 h-1 (B4)
Trial: 8280546
Drug: No background
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No background infusion (B0)
Trial: 26771733
Drug: Eptifibatide (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (bolus plus infusion) 12-48 hours prior to surgery (N=72 patients)
Trial: 26771733
Drug: Eptifibatide (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (bolus plus infusion)
Trial: 24345886
Drug: 56.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 56.5 μg teriparatide
Trial: 22652160
Drug: Oxybutynin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin (5 mg) + Trospium Chloride (20 mg) administered 3 times a day and 4 times a day respectively in Group A
Trial: 22652160
Drug: Oxybutynin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin (5 mg) + Solifenacin (10 mg) administered 3 times a day and once daily respectively in Group B
Trial: 17392649
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d), and tinidazole (500 mg b.d.) with bovine lactoferrin (200 mg b.d)
Trial: 17392649
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC, 400 mg b.d.), esomeprazole (40 mg/day), amoxycillin (1 g t.d), and tinidazole (500 mg b.d.) without bovine lactoferrin
Trial: 10197573
Drug: Tomato diet
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato diet (16.5 mg lycopene)
Trial: 27614452
Drug: Photoelectric and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photoelectric and musical treatment group (Group 1)
Trial: 27614452
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo group (Group 3)
Trial: 18629567
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention (mailed reminder, treatment guidelines, educational package)
Trial: 16775668
Drug: Xuezhikang (XZK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (XZK) 1,200 mg daily for 6 weeks, then replaced by placebo (XZK discontinued group; n = 25)
Trial: 16775668
Drug: Xuezhikang (XZK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (XZK) 1,200 mg daily throughout the study (XZK continued group; n = 25)
Trial: 15030293
Drug: Ezetimibe (Zetia)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (Zetia) as monotherapy
Trial: 15030293
Drug: Ezetimibe coadministered
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe coadministered with statins (simvastatin, atorvastatin, lovastatin, or pravastatin)
Trial: 10944137
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) using cyclophosphamide, carmustine, and etoposide (CBV regimen) followed by stem-cell transplantation
Trial: 10944137
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (ifosfamide plus etoposide, asparaginase, and cytarabine)
Trial: 8596127
Drug: co-amoxiclav (amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-amoxiclav (amoxicillin 875 mg + clavulanic acid 125 mg) twice daily for 10 days
Trial: 8596127
Drug: cefixime (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefixime (400 mg) once daily for 10 days
Trial: 8596127
Drug: ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin (500 mg) twice daily for 10 days
Trial: 2172578
Drug: Enrich (12.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrich (12.8 g of dietary fiber per 1000 kcal)
Trial: 26445227
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Iodine-125 brachytherapy and DP regimen (docetaxel 60 mg/m²/cisplatin 75 mg/m²)
Trial: 26445227
Drug: DP chemotherapy
RxNorm normalized name: prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DP chemotherapy
Trial: 17229894
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of DHA
Trial: 17229894
Drug: 1252 mg
RxNorm normalized name: Mg
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1252 mg of DHA + EPA
Trial: 14637268
Drug: Urate 1000
RxNorm normalized name: methenamine hippurate 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urate 1000 mg intravenously over 1 h
Trial: 14637268
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 1000 mg intravenously over 1 h
Trial: 10618558
Drug: Tranilast (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranilast (300 and 450 mg twice daily for 1 or 3 months)
Trial: 2834500
Drug: Kabi 2165
RxNorm normalized name: immunoglobulin G, human Injectable Solution [Kabiglobulin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kabi 2165 (n = 40): 2,500 U anti‐Xa preoperatively and evening of operation and 2,500 U anti‐Xa morning and evening daily up to the 9th or 10th day postoperatively
Trial: 2834500
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (n = 40): 3,750 U preoperatively and then 8 hourly, adjusted with thrombin time and cephalin + activator time, daily up to the 9th or 10th day
Trial: 2834500
Drug: Overall tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall tolerance evaluated from hemoglobin and hematocrit values, intra‐ and post‐operative bleeding, operation wound hematoma, and injection site
Trial: 27023086
Drug: TNF-α inhibitors
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNF-α inhibitors
Trial: 25057084
Drug: S-1 maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 maintenance chemotherapy (40 mg/m², twice daily for 14 days; 21 days for a treatment cycle)
Trial: 25057084
Drug: S-1 maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 maintenance chemotherapy
Trial: 21170108
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (lamivudine 100 mg/d for 32 weeks + interferon alpha 2b 5 million units every other day for 24 weeks)
Trial: 21170108
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy (100 mg/d for 48 weeks)
Trial: 21170108
Drug: Interferon monotherapy
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon monotherapy (5 million units every other day for 24 weeks)
Trial: 12957262
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy delay of 0-9 days
Trial: 12957262
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy delay of 10+ days
Trial: 9034556
Drug: Saruplase (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saruplase (80 mg)
Trial: 1848607
Drug: Calcium‐entry blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium‐entry blocker flunarizine (random treatment)
Trial: 26609642
Drug: Tutomesh TUTOGEN
RxNorm normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tutomesh TUTOGEN biological prosthesis reinforcement parietal herniorrhaphy (Group B)
Trial: 25275513
Drug: α-defensins and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-defensins and secretory leukocyte protease inhibitor (SLPI) levels
Trial: 22510426
Drug: 10 weekly
RxNorm normalized name: donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weekly individual child CBT sessions and 2 parent sessions
Trial: 19460773
Drug: G‐CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (5 microg/kg, twice a day for 3 days)
Trial: 2729751
Drug: Inspiratory flow
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory flow resistive loads (4.5 to 27.0 cm H2O/L/s)
Trial: 28426123
Drug: Cabozantinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (100 mg daily for 12 weeks)
Trial: 19637480
Drug: Agar/alginate combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agar/alginate combination impression
Trial: 9037444
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg once daily) alone (group A) for 4 weeks
Trial: 9037444
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg once daily) + tripotassium dicitrato bismuthate (TDB; 240 mg bid) for 4 weeks (group B)
Trial: 9037444
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg bid) for 2 weeks + amoxicillin (1 g bid only 2nd week) (group A)
Trial: 9037444
Drug: Tripotassium dicitrato
RxNorm normalized name: Tripotassium dicitratobismuthate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripotassium dicitrato bismuthate (TDB) monotherapy for 4 weeks (group B)
Trial: 8100221
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral (10 mg) and i.m. (0.5 mg) medication
Trial: 8100221
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral dosing (5 mg on trial days 1, 2, 3, 5, 7, 9, 11 and 13)
Trial: 8100221
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral dosing (5 mg on trial days 5 to 14) with initial i.m. loading doses (0.5 mg i.m. on trial days 1, 2 and 4)
Trial: 8100221
Drug: i.m. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. administration
Trial: 3729461
Drug: IHC (angiotensin-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IHC (angiotensin-induced hypertension chemotherapy)
Trial: 7797925
Drug: Trivalent cold-adapted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent cold-adapted recombinant (CR) influenza virus vaccine
Trial: 7797925
Drug: Monovalent A/H1N1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent A/H1N1, A/H3N2, or B vaccine
Trial: 2159706
Drug: Weekly intermittent
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly intermittent regimen of AZT and 2',3'-dideoxycytidine
Trial: 2159706
Drug: Weekly alternating
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly alternating regimen of AZT and 2',3'-dideoxycytidine
Trial: 2159706
Drug: Monthly alternating
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly alternating regimen of AZT and 2',3'-dideoxycytidine
Trial: 30277627
Drug: Intravaginal ulinastatin
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal ulinastatin (UTI) administration
Trial: 27690682
Drug: Nitroglycerin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (6 puffs, 2.4 mg sublingual) and glucagon (1 mg intravenously)
Trial: 27690682
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water (6 puffs) and hyoscine-n-butyl bromide (20 mg intravenously)
Trial: 25427566
Drug: CPP‐ACP‐containing cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP‐ACP‐containing cream (GC Tooth Mouse, non‐fluoride) after fluoride toothpaste (1,400 ppm NaF)
Trial: 23617551
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 μg
Trial: 23617551
Drug: Budesonide 400
RxNorm normalized name: Budesonide 400 microgram/actuation powder for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 400 μg + Formoterol 12 μg
Trial: 22084331
Drug: Dosing assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing assessment every 12 weeks (n = 124)
Trial: 22084331
Drug: Dosing assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing assessment every 4 weeks (n = 126)
Trial: 17218576
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg; maximum, 10 mg)
Trial: 16398842
Drug: Bisphosphonate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate therapy (n = 5)